231 related articles for article (PubMed ID: 29783798)
1. [Prognosis-related clinicopathologic characteristics of FIGO stage Ⅰ Müllerian adenosarcoma of uterus].
Wang Y; Liu AJ; Chen X; Song X
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):334-338. PubMed ID: 29783798
[No Abstract] [Full Text] [Related]
2. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
Gallardo A; Prat J
Am J Surg Pathol; 2009 Feb; 33(2):278-88. PubMed ID: 18941402
[TBL] [Abstract][Full Text] [Related]
3. Cluster of uterine mullerian adenosarcoma in the Washington, DC metropolitan area with high incidence of sarcomatous overgrowth.
Seidman JD; Wasserman CS; Aye LM; MacKoul PJ; O'Leary TJ
Am J Surg Pathol; 1999 Jul; 23(7):809-14. PubMed ID: 10403304
[TBL] [Abstract][Full Text] [Related]
4. Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma.
El Hallani S; Arora R; Lin DI; Måsbäc A; Mateoiu C; McCluggage WG; Nucci MR; Otis CN; Parkash V; Parra-Herran C; Longacre TA
Am J Surg Pathol; 2021 Mar; 45(3):374-383. PubMed ID: 33565764
[TBL] [Abstract][Full Text] [Related]
5. High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior.
Hodgson A; Amemiya Y; Seth A; Djordjevic B; Parra-Herran C
Am J Surg Pathol; 2017 Nov; 41(11):1513-1522. PubMed ID: 28834809
[TBL] [Abstract][Full Text] [Related]
6. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases.
Soslow RA; Ali A; Oliva E
Am J Surg Pathol; 2008 Jul; 32(7):1013-21. PubMed ID: 18469708
[TBL] [Abstract][Full Text] [Related]
7. [Recurrent Müllerian adenofibroma of uterus: a clinicopathologic study of 7 cases].
Shi H; Chen X; Zhang X; Zhou C; Yu M
Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):321-5. PubMed ID: 25030865
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study.
Mikami Y; Hata S; Kiyokawa T; Manabe T
Mod Pathol; 2002 Sep; 15(9):923-30. PubMed ID: 12218209
[TBL] [Abstract][Full Text] [Related]
9. Mullerian adenosarcoma of the female genital tract.
McCluggage WG
Adv Anat Pathol; 2010 Mar; 17(2):122-9. PubMed ID: 20179434
[TBL] [Abstract][Full Text] [Related]
10. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes.
Nathenson MJ; Conley AP; Lin H; Fleming N; Lazar A; Wang WL; Ravi V
Int J Gynecol Cancer; 2018 Sep; 28(7):1297-1310. PubMed ID: 30044322
[TBL] [Abstract][Full Text] [Related]
11. Clinical management of uterine cervical mullerian adenosarcoma: A clinicopathological study of six cases and review of the literature.
Togami S; Kawamura T; Fukuda M; Yanazume S; Kamio M; Kobayashi H
Taiwan J Obstet Gynecol; 2018 Aug; 57(4):479-482. PubMed ID: 30122564
[TBL] [Abstract][Full Text] [Related]
12. Uterine Adenosarcoma: a Review.
Nathenson MJ; Ravi V; Fleming N; Wang WL; Conley A
Curr Oncol Rep; 2016 Nov; 18(11):68. PubMed ID: 27718181
[TBL] [Abstract][Full Text] [Related]
13. Mesodermal (müllerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature.
Eichhorn JH; Young RH; Clement PB; Scully RE
Am J Surg Pathol; 2002 Oct; 26(10):1243-58. PubMed ID: 12360039
[TBL] [Abstract][Full Text] [Related]
14. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.
Rovirosa A; Ascaso C; Ordi J; Abellana R; Arenas M; Lejarcegui JA; Pahisa J; Puig-Tintoré LM; Mellado B; Armenteros B; Iglesias X; Biete A
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1320-9. PubMed ID: 11955745
[TBL] [Abstract][Full Text] [Related]
15. Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.
Friedlander ML; Covens A; Glasspool RM; Hilpert F; Kristensen G; Kwon S; Selle F; Small W; Witteveen E; Russell P
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S78-82. PubMed ID: 25341585
[TBL] [Abstract][Full Text] [Related]
16. CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma.
Van Mieghem T; Abeler VM; Moerman P; Verbist L; Vergote I; Amant F
Gynecol Oncol; 2005 Nov; 99(2):493-6. PubMed ID: 16051333
[TBL] [Abstract][Full Text] [Related]
17. The Impact on Survival of an Extensive Sex Cord-like Component in Mullerian Adenosarcomas: A Study Comprising 6 Cases.
Stolnicu S; Molnar C; Barsan I; Boros M; Nogales FF; Soslow RA
Int J Gynecol Pathol; 2016 Mar; 35(2):147-52. PubMed ID: 26535983
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of CD10 antigen in uterine adenosarcoma.
Amant F; Steenkiste E; Schurmans K; Verbist L; Abeler VM; Tulunay G; de Jonge E; Massuger L; Moerman P; Vergote I
Int J Gynecol Cancer; 2004; 14(6):1118-21. PubMed ID: 15571618
[TBL] [Abstract][Full Text] [Related]
19. Uterine Adenosarcoma.
Ulrich UA; Denschlag D
Oncol Res Treat; 2018; 41(11):693-696. PubMed ID: 30326467
[TBL] [Abstract][Full Text] [Related]
20. Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study.
Seagle BL; Kanis M; Strohl AE; Shahabi S
Gynecol Oncol; 2016 Dec; 143(3):636-641. PubMed ID: 27771166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
